Holen Sie sich die Stockscreener-App
0.9087
5.19%
0.0448
Vorhandelsmarkt:
.91
0.0013
+0.14%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ESPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$0.8639
Offen:
$0.87
24-Stunden-Volumen:
6.17M
Relative Volume:
1.23
Marktkapitalisierung:
$180.10M
Einnahmen:
$116.33M
Nettoeinkommen (Verlust:
$-209.25M
KGV:
-0.4286
EPS:
-2.12
Netto-Cashflow:
$-135.49M
1W Leistung:
+16.40%
1M Leistung:
-4.35%
6M Leistung:
-62.29%
1J Leistung:
-63.36%
1-Tages-Spanne:
$0.855
$0.9196
1-Wochen-Bereich:
$0.6925
$0.9196
52-Wochen-Spanne:
$0.6925
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Firmenname
Esperion Therapeutics Inc
Sektor
Telefon
734-887-3903
Adresse
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Vergleichen Sie ESPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
0.9087 | 154.73M | 116.33M | -209.25M | -135.49M | -2.12 |
|
HLN
Haleon Plc Adr
|
11.02 | 47.07B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
163.65 | 71.42B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.90 | 3.34M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.27 | 42.86B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.78 | 20.05B | 16.54B | -1.64B | 749.00M | -1.45 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-18 | Eingeleitet | Goldman | Neutral |
| 2024-12-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-06-20 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-08-01 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | Hochstufung | BofA Securities | Underperform → Buy |
| 2023-03-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-03-16 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | Fortgesetzt | BofA Securities | Neutral |
| 2023-02-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-02-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-03-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-19 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | Herabstufung | Stifel | Buy → Hold |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-12 | Herabstufung | Jefferies | Buy → Hold |
| 2021-02-09 | Herabstufung | Goldman | Neutral → Sell |
| 2021-01-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-10 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Underweight |
| 2020-08-11 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-03-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-24 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-16 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-29 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-06 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | Hochstufung | Goldman | Sell → Neutral |
| 2019-03-13 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-07 | Bestätigt | Needham | Strong Buy |
| 2018-12-13 | Eingeleitet | Goldman | Sell |
| 2018-10-29 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | Eingeleitet | BTIG Research | Buy |
| 2018-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-07-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-05-02 | Herabstufung | BofA/Merrill | Buy → Underperform |
Alle ansehen
Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten
Esperion at H.C. Wainwright Conference: Strategic Growth and Future Plans - Investing.com
Esperion to Participate in Upcoming June Investor Conferences - GlobeNewswire
Micro Labs Agrees To 15-Year Freeze On US Bempedoic Acid Rival - insights.citeline.com
Esperion Therapeutics, Micro Labs Settle Generic Nexletol Patent Dispute - marketscreener.com
Esperion reaches settlement agreement with Micro Labs - TipRanks
Esperion Settles Patent Litigation With Micro Labs For Generic Nexletol - Nasdaq
Esperion (ESPR) Reaches Settlement with Micro Labs Over Patent D - GuruFocus
Esperion Reaches Settlement Agreement With ANDA Filer Not To Market Generic Version Of Nexletol - marketscreener.com
Esperion Settles Patent Litigation with Micro Labs Regarding NEXLETOL Generic Marketing Rights - Nasdaq
Esperion Reaches Settlement Agreement with ANDA Filer Not - GlobeNewswire
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 - The Globe and Mail
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down - The Globe and Mail
HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines - Yahoo Finance
Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference - GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Esperion at The Citizens JMP Life Sciences Conference: Strategic Growth Insights - Investing.com India
Esperion Therapeutics Q1 2025 Earnings Preview - MSN
Esperion and HLS partner to commercialize heart disease treatments in Canada - Seeking Alpha
ESPR Secures Canadian Distribution Deal for NEXLETOL and NEXLIZE - GuruFocus
Esperion Therapeutics Enters License and Distribution Agreement with HLS Therapeutics - marketscreener.com
HLS Therapeutics Partners with Esperion to Bring Cardiovascular Treatments to Canada - TipRanks
Esperion secures Canadian rights deal for heart drugs - Investing.com
Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada - The Manila Times
Esperion Enters License Agreement with HLS Therapeutics to Expand Access to Bempedoic Acid Products in Canada - Nasdaq
Esperion secures Canadian rights deal for heart drugs By Investing.com - Investing.com Canada
Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and ... - Bluefield Daily Telegraph
Esperion Therapeutics (ESPR) Partners with HLS Therapeutics to Commercialize NEXLETOL and NEXLIZET in Canada - StreetInsider
HLS Therapeutics Announces Q1 2025 Financial Results - Yahoo Finance
Esperion Partners with HLS Therapeutics to Commercialize - GlobeNewswire
Esperion outlines Q2 prescription growth, targets triple combo launch by 2027 - MSN
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2025 Earnings Call Transcript - Insider Monkey
Esperion Therapeutics: Q1 Earnings Snapshot - Norwalk Hour
Esperion Therapeutics Reports Strong Q1 2025 Earnings - TipRanks
Earnings call transcript: Esperion Q1 2025 misses EPS forecast, revenue grows - Investing.com Nigeria
Esperion Therapeutics (ESPR) Reports Strong Q1 2025 Revenue Grow - GuruFocus
Esperion Therapeutics (ESPR) Reports Strong Q1 2025 Revenue Growth - GuruFocus
Esperion Q1 2025 slides: U.S. product sales surge 41% amid strategic expansion - Investing.com India
Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
ESPERION THERAPEUTICS Earnings Results: $ESPR Reports Quarterly Earnings - Nasdaq
Esperion Reports First Quarter 2025 Financial Results - The Manila Times
BRIEF-Esperion Therapeutics Q1 Basic EPS USD -0.21 - TradingView
Esperion Therapeutics Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Press Release Distribution & PR Platform - ACCESS Newswire
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Finanzdaten der Esperion Therapeutics Inc-Aktie (ESPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.37%
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):